REG - Alliance Pharma PLC - Posting of Annual Report and Notice of AGM

Alliance PharmaAnnouncement

12/04/2022 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220412:nRSL1058Ia&default-theme=true

RNS Number : 1058I  Alliance Pharma PLC  12 April 2022

 

 For immediate release  12 April 2022

 

 

 

 

ALLIANCE PHARMA

("Alliance" or the "Group")

 

Posting of Annual Report and Notice of AGM

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
that the Annual Report and Accounts for the year ended 31 December 2021, and
the notice of the 2022 AGM meeting to be held on 18 May, have now been posted
to those shareholders who have opted out of receiving electronic
communications from the Group.

 

Printed copies of the documents are also available by contacting Buchanan by
email at alliancepharma@buchanan.uk.com
(mailto:alliancepharma@buchanan.uk.com) or by telephoning Buchanan on 020 7466
5000.

 

 

For further information:

 

 Alliance Pharma plc                                                       + 44 (0)1249 466966
 Cora McCallum, Head of Investor Relations & Corporate Communications      + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                  + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited                                                  + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 Investec Bank plc                                                         + 44 (0)20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBKBBNFBKKNQD